-
Platinum-based chemotherapy for early triple-negative breast cancer Breast (IF 3.9) Pub Date : 2024-03-12 Sofia RE. Mason, Melina L. Willson, Sam J. Egger, Jane Beith, Rachel F. Dear, Annabel Goodwin
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer associated with shorter survival and a higher likelihood of the cancer returning. In early TNBC, platinum-based chemotherapy has been shown to improve pathological complete response (pCR); however, its effect on long-term survival outcomes has not been fully elucidated. Randomised controlled trials examining neoadjuvant
-
Gender minorities in breast cancer – Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients Breast (IF 3.9) Pub Date : 2024-03-09 Federica Miglietta, Letizia Pontolillo, Carmine De Angelis, Roberta Caputo, Monica Marino, Emilio Bria, Rossana Di Rienzo, Annarita Verrazzo, Carlo Buonerba, Giampaolo Tortora, Giuseppe Di Lorenzo, Lucia Del Mastro, Mario Giuliano, Filippo Montemurro, Fabio Puglisi, Valentina Guarneri, Michelino De Laurentiis, Luca Scafuri, Grazia Arpino
The last years have seen unprecedented improvement in breast cancer (BC) survival rates. However, this entirely apply to female BC patients, since gender minorities (male, transgender/gender-diverse) are neglected in BC phase III registration clinical trials. We conducted a scoping review of phase III clinical trials of agents with a current positioning within the therapeutic algorithms of BC. We selected
-
Skin perfusion and oxygen saturation after mastectomy and radiation therapy in breast cancer patients Breast (IF 3.9) Pub Date : 2024-03-06 Sherif Elawa, Ingemar Fredriksson, Ingrid Steinvall, Johan Zötterman, Simon Farnebo, Erik Tesselaar
The pathophysiological mechanism behind complications associated with postmastectomy radiotherapy (PMRT) and subsequent implant-based breast reconstruction are not completely understood. The aim of this study was to examine if there is a relationship between PMRT and microvascular perfusion and saturation in the skin after mastectomy and assess if there is impaired responsiveness to a topically applied
-
Accuracy of sentinel lymph node biopsy in male breast cancer: Systematic review and meta-analysis Breast (IF 3.9) Pub Date : 2024-03-05 Guillaume Parpex, Marie Ottaviani, Henri Lorphelin, Matthieu Mezzadri, Eva Marchand, Laurence Cahen-Doidy, Jean Louis Benifla, Cyrille Huchon, Camille Mimoun
Sentinel lymph node biopsy (SLNB) is commonly used in the surgical management of male breast cancer. Contrary to female breast cancer, limited data exist about its performance in male breast cancer. The objective of this systematic review and meta-analysis was to evaluate the SLNB accuracy in male breast cancer. MEDLINE, EMBASE, Web of Science and The Cochrane Library were searched from January 1995
-
Patients' and doctors’ views and experiences of the patient safety trajectory of breast cancer care Breast (IF 3.9) Pub Date : 2024-02-29 Clara Forrest, Martin J. O'Sullivan, Max Ryan, Colm O'Tuathaigh, Tara Jane Browne, Kathy Rock, Mary Jane O'Leary, Deirdre Madden, Seamus O'Reilly
Successful breast cancer outcomes can be jeopardised by adverse events. Understanding and integrating patients' and doctors’ perspectives into care trajectories could improve patient safety. This study assessed their views on, and experiences of, medical error and patient safety. A cross-sectional, quantitative 20–40 item questionnaire for patients attending Cork University Hospital Cancer Centre and
-
Predictors of re-attendance at biennial screening mammography following a false positive referral: A study among women in the south of the Netherlands Breast (IF 3.9) Pub Date : 2024-02-27 Adri C. Voogd, Zsófi Molnar, Joost Nederend, Robert-Jan Schipper, Luc J.A. Strobbe, Lucien E.M. Duijm
A false positive (FP) referral after screening mammography may influence a woman's likelihood to re-attend the screening program. The impact of having a FP result in the first or subsequent screening round on re-attendance after a FP result was investigated. In addition, we aimed to study differences in re-attendance rates between women who underwent non-invasive and invasive additional examinations
-
2023 Year in review: Early breast cancer Breast (IF 3.9) Pub Date : 2024-02-24 Guilherme Nader-Marta, Ann H. Partridge
The results of several studies aiming to tailor early breast cancer treatment to individual risk were released in 2023. Axillary lymph node dissections and radiotherapy may be safely omitted in carefully selected patients. Sustained benefit from adjuvant CDK4/6 inhibitors was observed in high-risk hormone receptor-positive disease and the addition of immunotherapy to neoadjuvant chemotherapy improved
-
Breast-conserving surgery is not associated with increased local recurrence in patients with early-stage node-negative triple-negative breast cancer treated with neoadjuvant chemotherapy Breast (IF 3.9) Pub Date : 2024-02-24 David Krug, Valentina Vladimirova, Michael Untch, Thorsten Kühn, Andreas Schneeweiss, Carsten Denkert, Beyhan Ataseven, Christine Solbach, Bernd Gerber, Hans Tesch, Michael Golatta, Sabine Seiler, Jörg Heil, Valentina Nekljudova, Johannes Holtschmidt, Sibylle Loibl
Neoadjuvant chemotherapy (NACT) is routinely used for patients with triple-negative breast cancer (TNBC). Upfront breast-conserving therapy (BCT) consisting of breast-conserving surgery (BCS) and adjuvant radiotherapy (RT) has been shown to be associated with improved outcome in patients with early TNBC as compared to mastectomy. We identified 2632 patients with early TNBC from the German Breast Group
-
The impact of breast density notification on psychosocial outcomes in racial and ethnic minorities: A systematic review Breast (IF 3.9) Pub Date : 2024-02-22 J.M.J. Isautier, S. Wang, N. Houssami, K. McCaffery, M.E. Brennan, T. Li, B. Nickel
High breast density is an independent risk factor for breast cancer and decreases the sensitivity of mammography. This systematic review synthesizes the evidence on the impact of breast density (BD) information and/or notification on women's psychosocial outcomes among women from racial and ethnic minority groups. A systematic search was performed in March 2023, and the articles were identified using
-
Effectiveness of hybrid digital breast tomosynthesis/digital mammography compared to digital mammography in women presenting for routine screening at Maroondah BreastScreen: Study protocol for a co-designed, non-randomised prospective trial Breast (IF 3.9) Pub Date : 2024-02-21 Nehmat Houssami, Darren Lockie, Michelle Giles, Sally Doncovio, Georgina Marr, David Taylor, Tong Li, Brooke Nickel, M Luke Marinovich
Digital breast tomosynthesis (DBT) for breast cancer screening has been shown in international trials to increase cancer detection compared with mammography; however, results have varied across screening settings, and currently there is limited and conflicting evidence on interval cancer rates (a surrogate for screening effectiveness). Australian pilot data also indicated substantially longer screen-reading
-
Stakeholders' experiences and perceptions of male breast cancer:A qualitative evidence synthesis Breast (IF 3.9) Pub Date : 2024-02-20 Maodie Ye, Lin Qiu, Yongmei Jin, Yingying Huang
-
Best of the year: Advanced breast cancer in 2023 Breast (IF 3.9) Pub Date : 2024-02-14 Ilana Schlam, Mariana Chavez-MacGregor
-
21-gene recurrence score in predicting the outcome of postoperative radiotherapy in T1-2N1 luminal breast cancer after breast-conserving surgery Breast (IF 3.9) Pub Date : 2024-02-12 Shang-Jin Xie, Run-Jie Wang, San-Gang Wu, Fu-Xing Zhang
In those with one to three positive lymph nodes (N1) breast cancer (BC), the 21-gene recurrence score (RS) classification can be referred for decision-making on adjuvant chemotherapy. This study aimed to investigate the effect of RS in predicting the survival benefit of postoperative radiotherapy (PORT) in T1-2N1 BC with estrogen receptor-positive and human epidermal growth factor receptor 2-negative
-
Seizing the moment: The time for harnessing electronic patient-reported outcome measures for enhanced and sustainable metastatic breast cancer care is now Breast (IF 3.9) Pub Date : 2024-02-11 K.M. de Ligt, L.B. Koppert, B.H. de Rooij, L.V. van de Poll-Franse, G. Velikova, F. Cardoso
The sustainability of healthcare systems is under pressure. Unlike care for many other chronic diseases, cancer care has yet to empower patients in effectively self-managing both the medical and emotional consequences of their condition, including adapting to changes in lifestyle and work, which is essential to achieve optimal health and recovery. Although proposed as a potential solution for sustainable
-
The efficacy of sensory nerve coaptation in DIEP flap breast reconstruction – Preliminary results of a double-blind randomized controlled trial Breast (IF 3.9) Pub Date : 2024-02-09 Jeske M. Bubberman, Lloyd Brandts, Sander M.J. van Kuijk, René R.W.J. van der Hulst, Stefania M.H. Tuinder
Sensory nerve coaptation has great potential to restore sensation after autologous breast reconstruction. However, blinded and randomized studies are lacking. We therefore present the preliminary results of our ongoing double-blinded randomized controlled trial that compares sensory recovery of innervated versus non-innervated DIEP flaps. Patients who underwent DIEP flap breast reconstruction between
-
Is circulating tumor cell count-driven cost-effective for first-line therapy choice in HR+/HER2- metastatic breast cancer in the United States? Breast (IF 3.9) Pub Date : 2024-02-09 Huiting Lin, Wenhua Wu, Xiaoya Lou, Yiming Wang, Hong Sun, Jiaqin Cai, Suyan Liu, Xiaoxia Wei
Circulating tumor cell (CTC) counting may be a useful non-invasive biomarker that helps patients choose first-line treatment options. Nevertheless, the cost of CTC inspection may impose an economic burden on patients, necessitating the simultaneous consideration of both its clinical effectiveness and cost. We evaluated the cost-effectiveness of CTC count-guided chemotherapy and endocrine therapy as
-
Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study Breast (IF 3.9) Pub Date : 2024-02-09 Gilles Freyer, Noelia Martinez-Jañez, Bożena Kukielka-Budny, Malgorzata Ulanska, Hugues Bourgeois, Montserrat Muñoz, Serafin Morales, Juan Bayo Calero, Laura Cortesi, Tamás Pintér, Markéta Palácová, Nelli Cherciu, Edgar Petru, Johannes Ettl, Cécilia de Almeida, Gustavo Villanova, Romain Raymond, Christine T.T. Minh, Ana Rodrigues, Marina E. Cazzaniga
Single-agent oral vinorelbine is a standard of care for hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) that has progressed on endocrine therapy. Metronomic administration may offer a better balance of efficacy and safety than standard regimens, but data from previous trials are scarce. In this open-label, multicenter, phase II trial
-
Interactive multidisciplinary pilot workshop to improve medical student perception of and interest in breast surgical oncology Breast (IF 3.9) Pub Date : 2024-02-09 Amani Raheel, Shreeya Dalla, Jalee Birney, Allison M. Aripoli, Meredith Collins, Kelsey E. Larson, Jamie L. Wagner, Christa R. Balanoff, Jordan Baker, Lynn Chollet-Hinton, Lyndsey J. Kilgore
Exposure to breast surgical oncology (BSO) and the multidisciplinary management of patients with breast cancer is limited in medical school. The purpose of this study was to assess changes in student perceptions of BSO as a career following an interactive multidisciplinary workshop. Pre-clinical medical students participated in a multidisciplinary, hands-on workshop, composed of breast radiology (BR)
-
Acceptance of outpatient enhanced recovery after surgery (ERAS©) protocols for implant-based breast reconstruction nudged on by the COVID-19 pandemic Breast (IF 3.9) Pub Date : 2024-02-09 Alexandra Hatchell, Mariam Osman, Jody Bielesch, Claire Temple-Oberle
We retrospectively identified 295 women undergoing outpatient implant breast reconstruction (IBR) who received standardized ERAS care pre-pandemic (PP; April 2018–March 2020) and during the pandemic (DP; April 2020–March 2022). The majority of IBR was completed as outpatient surgeries DP versus PP (73% versus 38%, p < 0.001). Immediate IBR increased DP versus PP (p < 0.001). Preoperative ERAS© order
-
“The Uncertainty Principle”– studying immediate lymphatic reconstruction impacts the natural history of breast cancer related lymphedema Breast (IF 3.9) Pub Date : 2024-02-05 Spencer Yakaback, Claire Temple-Oberle
Breast cancer-related lymphedema (BCRL) following axillary lymph node dissection (ALND) is a life-altering sequela for patients and a challenging problem for their surgeons. In order to prevent BCRL, immediate lymphatic reconstruction (ILR) is a surgical technique that has been devised to restore lymphatic drainage to the operative limb. Although ILR is becoming popular in the literature, we have identified
-
Local hero: A phase II study of local therapy only (stereotactic radiosurgery and / or surgery) for treatment of up to five brain metastases from HER2+ breast cancer. (TROG study 16.02) Breast (IF 3.9) Pub Date : 2024-02-05 Claire Phillips, Mark B. Pinkham, Alisha Moore, Joseph Sia, Rosalind L. Jeffree, Mustafa Khasraw, Anthony Kam, Mathias Bressel, Annette Haworth
Introduction, A decade ago, stereotactic radiosurgery (SRS) without whole brain radiotherapy (WBRT) was emerging as preferred treatment for oligometastatic brain metastases. Studies of cavity SRS after neurosurgery were underway. Data specific to metastatic HER2 breast cancer (MHBC), describing intracranial, systemic and survival outcomes without WBRT, were lacking. A Phase II study was designed to
-
Breast cancer highlights from 2023: Knowledge to guide practice and future research Breast (IF 3.9) Pub Date : 2024-01-27 Maria-Joao Cardoso, Philip Poortmans, Elżbieta Senkus, Oreste D. Gentilini, Nehmat Houssami
This narrative work highlights a selection of published work from 2023 with potential implications for breast cancer practice. We feature publications that have provided new knowledge immediately relevant to patient care or for future research. We also highlight guidelines that have reported evidence-based or consensus recommendations to support practice and evaluation in breast cancer diagnosis and
-
“Heterogeneity of treatment effect on patients’ long-term outcome according to pathological response type in neoadjuvant RCTs for breast cancer.” Breast (IF 3.9) Pub Date : 2024-01-19 Laura Pala, Isabella Sala, Eleonora Pagan, Tommaso De Pas, Emma Zattarin, Chiara Catania, Emilia Cocorocchio, Giovanna Rossi, Daniele Laszlo, Giovanni Ceresoli, Jacopo Canzian, Elena Valenzi, Vincenzo Bagnardi, Fabio Conforti
Introduction To provide evidence explaining the poor association between pCR and patients’ long-term outcome at trial-level in neoadjuvant RCTs for breast cancer (BC), we performed a systematic-review and meta-analysis of all RCTs testing neoadjuvant treatments for early-BC and reporting the hazard ratio of DFS (HRDFS) for the intervention versus control arm stratified by pathological response type
-
De-escalation of loco-regional treatments: Time to find a balance Breast (IF 3.9) Pub Date : 2024-01-16 Oreste D. Gentilini, Maria-Joao Cardoso, Elżbieta Senkus, Philip Poortmans
Abstract not available
-
The oncological safety and long-term cosmetic effect of free dermal fat graft with epidermis removal for breast defect repair in breast conserving surgery Breast (IF 3.9) Pub Date : 2024-01-04 Zikui Xiong, Jindi He, Xin Zhao, Xinqing Ye, Manlu Cui, Juan Fu, Jianlun Liu, Qiuyun Li
Background Free dermal fat grafts (FDFG) are used for immediate breast defect repair in breast-conserving surgery (BCS), and have achieved satisfactory immediate postoperative cosmetic effects (Sawai et al., 2004) [1]. However, the oncologic safety and long-term cosmetic outcomes of these surgical procedures remain unknown. Therefore, t,in this study, we aim to investigate the oncological safety and
-
New insights into HER2-low breast cancer brain metastasis: A retrospective analysis Breast (IF 3.9) Pub Date : 2024-01-01 Hangcheng Xu, Yan Wang, Li Li, Yiqun Han, Yun Wu, Qiang Sa, Binghe Xu, Jiayu Wang
Background A considerable number of patients with breast cancer will suffer from brain metastasis in the advanced setting. The HER2 status serves as a significant prognostic factor and the reference of applying treatment for patients with breast cancer brain metastasis (BCBM). Methods Between January 2010 and July 2021, patients with BCBM who had available HER2 status were identified. The patients
-
Axillary lymph node dissection in triple-negative or HER2-positive breast cancer patients with clinical N2 achieving pathological complete response after neoadjuvant therapy: Is it necessary? Breast (IF 3.9) Pub Date : 2024-01-05 Xuhui Guo, Jiao Zhang, Xilong Gong, Jia Wang, Hao Dai, Dechuang Jiao, Rui Ling, Yi Zhao, Hongjian Yang, Yunjiang Liu, Ke Liu, Jianguo Zhang, Dahua Mao, Jianjun He, Zhigang Yu, Yinhua Liu, Peifen Fu, Jiandong Wang, Hongchuan Jiang, Zuowei Zhao, Zhenzhen Liu
Aim:This study aims to identify suitable candidates for axillary sentinel lymph node biopsy (SLNB) or targeted axillary dissection (TAD) among clinical N2 (cN2) triple-negative (TN) or HER2 positive (HER2+)breast cancer patients following neoadjuvant therapy(NAT). Background: Despite the substantial axillary burden in cN2 breast cancer patients, high pathological response rates can be achieved with
-
Omission of radiation therapy post breast conserving surgery Breast (IF 3.9) Pub Date : 2024-01-05 Boon H. Chua
Radiation therapy (RT) after breast conserving surgery decreases the risks of local recurrence and breast cancer mortality in the multidisciplinary management of patients with breast cancer. However, breast cancer is a heterogeneous disease, and the absolute benefit of post-operative RT in individual patients varies substantially. Clinical trials aiming to identify patients with low-risk early breast
-
French college of gynecologists and obstetricians (CNGOF) recommendations for clinical practice: Place of breast self-examination in screening strategies Breast (IF 3.9) Pub Date : 2024-01-03 Vincent Lavoué, Amélia Favier, Frank Sophie, Gérard Boutet, Anne-Sophie Azuar, Susie Brousse, François Golfier, Catherine Uzan, Charlotte Vaysse, Sébastien Molière, Martine Boisserie-Lacroix, Edith Kermarrec, Jean-Yves Seror, Yann Delpech, Élisabeth Luporsi, Christine M. Maugard, Nicolas Taris, Nathalie Chabbert-Buffet, Jonathan Sabah, Khalid Alghamdi, Carole Mathelin
-
Corrigendum to ‘Assessment of deep learning-based auto-contouring on interobserver consistency in target volume and organs-at-risk delineation for breast cancer: Implications for RTQA program in a multi-institutional study’ [The Breast 73 (2024) 103599] Breast (IF 3.9) Pub Date : 2023-12-30 Min Seo Choi, Jee Suk Chang, Kyubo Kim, Jin Hee Kim, Tae Hyung Kim, Sungmin Kim, Hyejung Cha, Oyeon Cho, Jin Hwa Choi, Myungsoo Kim, Juree Kim, Tae Gyu Kim, Seung-Gu Yeo, Ah Ram Chang, Sung-Ja Ahn, Jinhyun Choi, Ki Mun Kang, Jeanny Kwon, Taeryool Koo, Mi Young Kim, Yong Bae Kim
Abstract not available
-
Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: A hellenic cooperative oncology group observational study (HE 10/10) with concurrent investigation of significance of tumor infiltrating lymphocytes Breast (IF 3.9) Pub Date : 2023-12-25 Foteinos-Ioannis Dimitrakopoulos, Anna Goussia, Georgia-Angeliki Koliou, Katerina Dadouli, Anna Batistatou, Helen P. Kourea, Mattheos Bobos, Petroula Arapantoni-Dadioti, Olympia Tzaida, Triantafyllia Koletsa, Sofia Chrisafi, Maria Sotiropoulou, Alexandra Papoudou-Bai, Irene Nicolaou, Antonia Charchanti, Davide Mauri, Gerasimos Aravantinos, Ioannis Binas, Eleni Res, Amanda Psyrri, George Fountzilas
Background Dose-dense sequential (dds) chemotherapy has changed the clinical outcome of patients with early breast cancer (BC). To investigate the impact of dose intensity (DI) in the adjuvant setting of BC, this observational trial (HE 10/10) was conducted assessing the long-term survival outcome, safety and toxicity of a currently widely used chemotherapeutic regimen. In addition, the prognostic
-
Clinicopathological characteristics and value of HER2-low expression evolution in breast cancer receiving neoadjuvant chemotherapy Breast (IF 3.9) Pub Date : 2023-12-22 Yingbo Shao, Huijuan Guan, Zhifen Luo, Yang Yu, Yaning He, Qi Chen, Chaojun Liu, Fangyuan Zhu, Hui Liu
Objective The present study aimed to evaluate the clinicopathological characteristics and value of HER2-low expression evolution in breast cancer receiving neoadjuvant chemotherapy (NAC). Methods Patients with HER2 negative breast cancer receiving NAC from January 2017 to December 2020 were enrolled in this study. The clinicopathological characteristics, response to NAC, evolution of HER2 and prognostic
-
Efficacy of antiandrogens in androgen receptor-positive triple-negative metastatic breast cancer: Real-life data Breast (IF 3.9) Pub Date : 2023-12-22 Yasmine Rhanine, Hervé Bonnefoi, Anthony Goncalves, Marc Debled, Sylvestre Le Moulec, Nathalie Bonichon, Gaetan Macgrogan, Monica Arnedos, Bénédicte Dubroca-Dehez, Thomas Grellety
Antiandrogens (AA) have been tested in clinical trials in androgen receptor (AR) + triple-negative breast cancer (TNBC). We aim to assess the clinical benefit rate (CBR) of AA in real life. The primary end-point was CBR at 6 months. Twenty-four patients were assessable and received: abiraterone acetate (62 %), enzalutamide (8 %) and bicalutamide (30 %). CBR at 6 months was 29 % (7/24) with 2 CR, 3 PR
-
Male breast cancer: No evidence for mosaic BRCA1 promoter methylation involvement Breast (IF 3.9) Pub Date : 2023-12-10 Mathias Schwartz, Sabrina Ibadioune, Sophie Vacher, Marie-Charlotte Villy, Olfa Trabelsi-Grati, Jessica Le Gall, Sandrine M. Caputo, Hélène Delhomelle, Mathilde Warcoin, Virginie Moncoutier, Christine Bourneix, Nadia Boutry-Kryza, Antoine De Pauw, Marc-Henri Stern, Bruno Buecher, Emmanuelle Mouret-Fourme, Chrystelle Colas, Dominique Stoppa-Lyonnet, Julien Masliah-Planchon, Lisa Golmard, Ivan Bieche
Breast cancers (BC) are rare in men and are often caused by constitutional predisposing factors. In women, mosaic BRCA1 promoter methylations (MBPM) are frequent events, detected in 4–8% of healthy subjects. This constitutional epimutation increases risk of early-onset and triple-negative BC. However, the role of MBPM in male BC predisposition has never been assessed. We screened 40 blood samples from
-
Is there a link between elevated C-reactive protein levels and specific breast cancer molecular subtypes? Breast (IF 3.9) Pub Date : 2023-12-09 Kadri Altundag
Abstract not available
-
Diagnostic delays in breast cancer among young women: An emphasis on healthcare providers Breast (IF 3.9) Pub Date : 2023-12-13 Luis Costa, Rakesh Kumar, Cynthia Villarreal-Garza, Saket Sinha, Sunil Saini, Jayanti Semwal, Vartika Saxsena, Vaishali Zamre, Chintamani Chintamani, Mukurdipi Ray, Chikako Shimizu, Lejla Hadzikadic Gusic, Masakazu Toi, Allan Lipton
Despite advances in breast cancer care, breast cancer in young women (BCYW) faces unique challenges, diagnostic delays, and limited awareness in many countries. Here, we discuss the challenges and consequences associated with the delayed diagnosis of BCYW. The consequences of delayed diagnosis in young women - which generally varies among developed, developing, or underdeveloped countries - are severe
-
Digital breast tomosynthesis versus X-ray of the breast specimen for intraoperative margin assessment: A randomized trial Breast (IF 3.9) Pub Date : 2023-12-01 Irina Palimaru Manhoobi, Trine Tramm, Søren Redsted, Anne Bodilsen, Leslie Foldager, Peer Christiansen
Background Involved resection margins after breast conserving surgery (BCS) often require a re-operation with increased patient anxiety and risk of impaired cosmesis. We investigated the number of re-operations due to involved resection margins after BCS comparing digital breast tomosynthesis(DBT) with X-ray for intraoperative margin evaluation. Furthermore, we assessed the diagnostic accuracy of these
-
Association of clinicopathologic variables and patient preference with the choice of surgical treatment for early-stage breast cancer: A registry-based study Breast (IF 3.9) Pub Date : 2023-11-30 Emma Söderberg, Fredrik Wärnberg, Anna-Karin Wennstig, Greger Nilsson, Hans Garmo, Lars Holmberg, Carl Blomqvist, Malin Sund, Charlotta Wadsten
Introduction Observational studies suggest that breast conserving surgery (BCS) and radiotherapy (RT) offers superior survival compared to mastectomy. The aim was to compare patient and tumour characteristics in women with invasive breast cancer ≤30 mm treated with either BCS or mastectomy, and to explore the underlying reason for choosing mastectomy. Methods Women registered with breast cancer ≤30 mm
-
Clinical implications of incorporating genetic and non-genetic risk factors in CanRisk-based breast cancer risk prediction Breast (IF 3.9) Pub Date : 2023-11-29 Anja Tüchler, Antoine De Pauw, Corinna Ernst, Amélie Anota, Inge M.M. Lakeman, Julia Dick, Nienke van der Stoep, Christi J. van Asperen, Monika Maringa, Natalie Herold, Britta Blümcke, Robert Remy, Anke Westerhoff, Denise J. Stommel-Jenner, Eléonore Frouin, Lisa Richters, Lisa Golmard, Nadine Kütting, Chrystelle Colas, Barbara Wappenschmidt, Eric Hahnen
Background Breast cancer (BC) risk prediction models consider cancer family history (FH) and germline pathogenic variants (PVs) in risk genes. It remains elusive to what extent complementation with polygenic risk score (PRS) and non-genetic risk factor (NGRFs) data affects individual intensified breast surveillance (IBS) recommendations according to European guidelines. Methods For 425 cancer-free
-
Real-world impact of dual anti-HER2 antibodies on cardiac function in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer Breast (IF 3.9) Pub Date : 2023-11-22 Kelvin KH. Bao, Jeffrey CH. Chan, Jocelyn G. Chan, Leone Sutanto, Ka Man Cheung, Harry HY. Yiu
Abstract not available
-
Development and evaluation of a decision aid for women eligible for organized breast cancer screening according to international standards: A multi-method study Breast (IF 3.9) Pub Date : 2023-11-25 Sandrine Hild, Delphine Teigné, Damien Fairier, Yannick Ruelle, Isabelle Aubin-Auger, Stéphanie Sidorkiewicz, Marie Citrini, Xavier Gocko, Catherine Cerisey, Emilie Ferrat, Cédric Rat
Background and purpose: In France, women lack information to make a shared decision to start breast cancer screening. Decision aids are useful to facilitate this discussion, yet few meet international standards. The objective of this project was to build, validate and measure the quality of a decision aid for organized breast screening in France, in line with international standards, intended for both
-
The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline CHEK2 c.1100delC families Breast (IF 3.9) Pub Date : 2023-11-25 Maartje A.C. Schreurs, Teresa Ramón y Cajal, Muriel A. Adank, J. Margriet Collée, Antoinette Hollestelle, Jeroen van Rooij, Marjanka K. Schmidt, Maartje J. Hooning
To determine the changes in surveillance category by adding a polygenic risk score based on 311 breast cancer (BC)-associated variants (PRS311), questionnaire-based risk factors and breast density on personalized BC risk in unaffected women from Dutch CHEK2 c.1100delC families. In total, 117 unaffected women (58 heterozygotes and 59 non-carriers) from CHEK2 families were included. Blood-derived DNA
-
Risk factors for late recurrence and postrelapse survival in estrogen receptor (ER)-positive, human epidermal growth factor receptor (HER) 2-negative breast cancer after 5 years of endocrine therapy Breast (IF 3.9) Pub Date : 2023-11-19 Masahiro Ito, Masakazu Amari, Akiko Sato, Masahiro Hikichi, Aru Sakamoto, Asumi Yamazaki, Shigehira Saji
It is unclear which patients with ER-positive, HER2-negative breast cancer benefit from extended endocrine therapy beyond 5 years. Prognostic factors for late-recurring breast cancer postrelapse survival have been reported. We retrospectively analyzed data from 892 patients with ER-positive and HER2-negative invasive breast cancer who were disease-free after completing a 5-year adjuvant endocrine therapy
-
Oncoplastic and reconstructive surgery in SENONETWORK Italian breast centers: lights and shadows Breast (IF 3.9) Pub Date : 2023-11-18 Matteo Ghilli, Andrea Vittorio Emanuele Lisa, Marzia Salgarello, Giovanni Papa, Mario Rietjens, Secondo Folli, Annalisa Curcio, Guglielmo Ferrari, Francesco Caruso, Vittorio Altomare, Daniele Friedman, Maria Carmen De Santis, Fiorenza De Rose, Bruno Meduri, Francesca De Felice, Lorenza Marino, Francesca Cucciarelli, Stefania Montemezzi, Pietro Panizza, Paolo Belli, Gretha Grilz
Abstract not available
-
Key factors in the decision-making process for mastectomy alone or breast reconstruction: A qualitative analysis Breast (IF 3.9) Pub Date : 2023-11-16 T. Blackmore, K. Norman, V. Burrett, J. Scarlet, I. Campbell, R. Lawrenson
Breast cancer is the most common cancer to affect New Zealand women. Women diagnosed face several decisions regarding surgical treatment, including whether to undergo lumpectomy, mastectomy, or breast reconstruction. Reconstructive surgery adds an additional layer of complexity, with several reconstructive options, each associated with differing surgical and recovery times. Furthermore, surgical decisions
-
Hematological and biochemical markers influencing breast cancer risk and mortality: Prospective cohort study in the UK Biobank by multi-state models Breast (IF 3.9) Pub Date : 2023-11-15 Yanyu Zhang, Xiaoxi Huang, Xingxing Yu, Wei He, Kamila Czene, Haomin Yang
Background Breast cancer is the most common cancer and the leading cause of cancer-related death among women. However, evidence concerning hematological and biochemical markers influencing the natural history of breast cancer from in situ breast cancer to mortality is limited. Methods In the UK Biobank cohort, 260,079 women were enrolled during 2006–2010 and were followed up until 2019 to test the
-
Assessment of deep learning-based auto-contouring on interobserver consistency in target volume and organs-at-risk delineation for breast cancer: Implications for RTQA program in a multi-institutional study Breast (IF 3.9) Pub Date : 2023-11-15 Min Seo Choi, Jee Suk Chang, Kyubo Kim, Jin Hee Kim, Tae Hyung Kim, Sungmin Kim, Hyejung Cha, Oyeon Cho, Jin Hwa Choi, Myungsoo Kim, Juree Kim, Tae Gyu Kim, Seung-Gu Yeo, Ah Ram Chang, Sung-Ja Ahn, Jinhyun Choi, Ki Mun Kang, Jeanny Kwon, Taeryool Koo, Mi Young Kim, Yong Bae Kim
Purpose To quantify interobserver variation (IOV) in target volume and organs-at-risk (OAR) contouring across 31 institutions in breast cancer cases and to explore the clinical utility of deep learning (DL)-based auto-contouring in reducing potential IOV. Methods and materials In phase 1, two breast cancer cases were randomly selected and distributed to multiple institutions for contouring six clinical
-
Patient-reported outcomes in bilateral prophylactic mastectomy with breast reconstruction: A narrative review Breast (IF 3.9) Pub Date : 2023-11-11 Pavla Ticha, Andrej Sukop
In women at high risk of developing breast cancer, bilateral prophylactic mastectomy (BPM) 1 significantly reduces the risk; simultaneously, breast reconstruction preserves body integrity. Given the complex and personal nature of such surgical procedures, patient assessment of satisfaction and health-related quality of life (HRQoL) 2 is essential in evaluation of surgical outcomes. With this review
-
Omitting radiotherapy in elderly breast cancer patients: Valid strategy or illusory hope? Breast (IF 3.9) Pub Date : 2023-11-08 Fadila Kouhen
Breast cancer treatment strategies have evolved significantly over the years, and decisions regarding the use of radiotherapy have become increasingly complex. This paper explores the considerations and limitations associated with omitting radiotherapy as part of breast cancer treatment. While omitting radiotherapy may be a viable option for select patient groups, it is not without its challenges.
-
Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel/carboplatin/trastuzumab/pertuzumab for HER2-positive breast cancer Breast (IF 3.9) Pub Date : 2023-10-30 Nalee Kim, Ji-Yeon Kim, Won Park, Won Kyung Cho, Tae Gyu Kim, Young-Hyuck Im, Jin Seok Ahn, Jeong Eon Lee, Seok Jin Nam, Seok Won Kim, Jonghan Yu, Byung Joo Chae, Sei Kyung Lee, Jai-Min Ryu, Yeon Hee Park, Haeyoung Kim
Aim The role of regional nodal irradiation (RNI) after preoperative systemic treatment (PST) with targeted therapy for HER2-positive breast cancer remains uncertain. This study aimed to investigate the impact of RNI on locoregional recurrence (LRR) and disease-free survival (DFS) outcomes after docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) for PST. Methods We retrospectively analyzed 255 patients
-
Masculinizing hormone therapy effect on breast tissue: Changes in estrogen and androgen receptors in transgender female-to-male mastectomies Breast (IF 3.9) Pub Date : 2023-11-03 Manita Chaum, Sara Grossi, Jiaxi Chen, Vivian Hu, Edward Ray, Armando Giuliano, Shikha Bose
Purpose Almost two percent of individuals in the United States identify as gender non-conforming. In the female-to-male (FTM) transgender population, masculinizing hormone therapy with testosterone is commonly prescribed in gender transition. To date, the effects of exogenous androgens on breast tissue and its roles in altering breast cancer risk are poorly understood. This study examines the histopathologic
-
Exploring the clinical outcomes and safety profile of inetetamab treatment in metastatic breast cancer patients: A multicenter assessment of a Chinese-origin recombinant Anti-HER2 monoclonal antibody Breast (IF 3.9) Pub Date : 2023-11-01 Binliang Liu, Ning Xie, Can Tian, Ronghua Feng, Zhe-Yu Hu, Jing Li, Liping Liu, Huawu Xiao, Xiaohong Yang, Mengsi Zeng, Hui Wu, Jun Lu, Jianxiang Gao, Xuming Hu, Min Cao, Zhengrong Shui, Yu Tang, Tao Wu, Quchang Ouyang
Background Inetetamab is a novel recombinant humanized anti-HER2 monoclonal antibody. This study aimed to evaluate the efficacy and safety of inetetamab and predictive factors for response in HER2-positive metastatic breast cancer (MBC) patients. Methods A cohort of HER2-positive MBC patients who received inetetamab-based therapy between June 2020 and August 2021 was evaluated. The primary endpoint
-
Correlation between the CEM imaging characteristics and different molecular subtypes of breast cancer Breast (IF 3.9) Pub Date : 2023-10-31 Na Li, Weiyun Gong, Yuanzhong Xie, Lei Sheng
Purpose To investigate the correlation between the contrast-enhanced mammography (CEM) imaging characteristics and different molecular subtypes of breast cancer (BC). Methods We retrospectively included 313 eligible female patients who underwent CEM examination and surgery in our hospital from July 2017 to July 2021. Their lesions were confirmed on histopathological examination and immunohistochemical
-
Trends in the pre-operative diagnosis and surgical management of axillary lymph node metastases in women with screen-detected breast cancer Breast (IF 3.9) Pub Date : 2023-10-21 Lucien E.M. Duijm, Luc J.A. Strobbe, Vivian van Breest Smallenburg, Clemence L. op de Coul-Froger, Wikke Setz-Pels, Willem Vreuls, Hermen C. van Beek, Rob M.G. van Bommel, Adri C. Voogd
Aim The aim of the current study was to investigate time-trends in pre-operative diagnosis and surgical treatment of axillary lymph node metastases in breast cancers detected at screening mammography. Methods We included all women who underwent screening mammography in the South of the Netherlands between 2005 and 2020. During a follow-up period of at least two years, data on clinical radiological
-
Breast cancer risk prediction using Tyrer-Cuzick algorithm with an 18-SNPs polygenic risk score in a European population with below-average breast cancer incidence Breast (IF 3.9) Pub Date : 2023-10-12 Tjaša Oblak, Petra Škerl, Benjamin J. Narang, Rok Blagus, Mateja Krajc, Srdjan Novaković, Janez Žgajnar
Goals To determine whether an 18 single nucleotide polymorphisms (SNPs) polygenic risk score (PRS18) improves breast cancer (BC) risk prediction for women at above-average risk of BC, aged 40–49, in a Central European population with BC incidence below EU average. Methods 502 women aged 40–49 years at the time of BC diagnosis completed a questionnaire on BC risk factors (as per Tyrer-Cuzick algorithm)
-
Our house believes that: The clipped lymph node is the true sentinel node after neoadjuvant chemotherapy in N+ patients Breast (IF 3.9) Pub Date : 2023-10-14 Benigno Acea-Nebril, Alejandra García-Novoa, Alberto Bouzón Alejandro, Carlota Díaz Carballada, Carmen Conde Iglesias
Axillary staging is an important prognostic factor in breast cancer, being sentinel lymph node biopsy (SLNB) the gold standard staging method in early stages. However, in clinically node positive (cN+) patients who converted to clinically node-negative (cN0) after primary systemic therapy (PST) the axillary staging method during surgery remains controversial. There are at least three validated methods:
-
Survival outcomes seen with neoadjuvant chemotherapy in the management of locally advanced inflammatory breast cancer (IBC) versus matched controls Breast (IF 3.9) Pub Date : 2023-10-14 Kai CC Johnson, Michael Grimm, Jasmine Sukumar, Patrick M. Schnell, Ko Un Park, Daniel G. Stover, Sachin R. Jhawar, Margaret Gatti-Mays, Robert Wesolowski, Nicole Williams, Sagar Sardesai, Ashley Pariser, Preeti Sudheendra, Gary Tozbikian, Bhuvaneswari Ramaswamy, Dureti Doto, Mathew A. Cherian
Inflammatory breast cancer (IBC) poses an ongoing challenge as rates of disease recurrence and mortality remain high compared to stage-matched controls. However, frontline therapy has evolved through the years, including the widespread use of neoadjuvant chemotherapy (NAC) given the prognostic importance of pathologic complete response (pCR). Due to these sweeping changes, we need new data to assess
-
Cost effectiveness of using trastuzumab biosimilars compared to trastuzumab original drugs to treat breast cancer in a hospital setting Breast (IF 3.9) Pub Date : 2023-10-11 Eric C. Barat, Marianne L.E. Arrii, Annaelle Soubieux-Bourbon, Mikaël Daouphars, Rémi Varin, Patrick R. Tilleul
Introduction Subcutaneous (SC) drug administration, such as the Herceptin® in an oncology day hospital reduces the administration time of trastuzumab. In the context of combination therapy administration, this time-saving may be called into question. The challenge posed by the deployment of much less expensive IV biosimilar forms raises questions about the cost-effectiveness of SC administration. Methods
-
Consumer experiences of shame in clinical encounters for breast cancer treatment. “Who do you think you are– Angelina Jolie?” Breast (IF 3.9) Pub Date : 2023-10-05 M.E. Brennan, K. Bell, G. Hamid, J. Gilchrist, J. Gillingham
Background Shame is a powerful negative emotion that has the potential to affect health. Due to the intimate nature of breast cancer treatment and its impact on body image, it is hypothesised that shame may be experienced during treatment. The aim of this study was to explore shame experiences related to clinical encounters for breast cancer treatment. Methods People with a lived experience of breast
-
Prognostic impact of reduced HER2 protein expression in post-neoadjuvant therapy resection specimens: A single institution experience and review of the literature Breast (IF 3.9) Pub Date : 2023-10-03 Jan Paredes Mogica, Haiming Tang, Yuanxin Liang, Minghao Zhong, Pei Hui, Malini Harigopal, Uma Krishnamurti, Neal A. Fischbach, Haiying Zhan
Background Retesting for Human epidermal growth factor receptor-2 (HER2) in post-neoadjuvant therapy resection is variable, and data is conflicting regarding the prognostic significance of changes in HER2 expression pre and post therapy. Methods We identified 104 patients with localized HER2 IHC 3+ breast cancer who received neoadjuvant trastuzumab(T)/pertuzumab(P) containing chemotherapy at Yale Cancer